Ascend Laboratories, LLC recalls
13 notices naming Ascend Laboratories, LLC as the recalling firm, since December 18, 2024. A notice covers specific products and lots, not every product of the firm.
Hazard and remedy text is quoted from the agency, unedited. The tag names the kind of risk with a word from that text. Every notice links to its official page.
Dissolution
Ascend Laboratories, LLC: Amlodipine and Olmesartan Medoxomil Tablets
Hazard (FDA): Out of specification due to dissolution.
FDAMedicines
Ascend Laboratories, LLC: Dabigatran Etexilate Capsules and 2 more
Hazard (FDA): Failed impurity/degradation specification: an OOS result observed in Related substance test analysis w.r.t Impurity II, Impurity III and Total impurities for 12-month stability
FDAMedicines
Dissolution
Ascend Laboratories, LLC: Amlodipine and Olmesartan Medoxomil Tablets
Hazard (FDA): Failed Dissolution Specifications; Olmesartan Medoxomil content below specifications
FDAMedicines
Ascend Laboratories, LLC: Dabigatran etexilate Capsules and 1 more
Hazard (FDA): Failed Impurities/Degradation Specifications: OOS result was observed during the related substance test analysis with respect to Impurity II, Impurity III and Total impurity testing for 12 Month Long-Term Stability.
FDAMedicines
Dissolution
Ascend Laboratories, LLC: Minocycline Hydrochloride Extended-Release Tablets
Hazard (FDA): Failed Dissolution Specifications: An out-of-specification (OOS) result was observed during the 9th month of dissolution test analysis
FDAMedicines
Dissolution
Ascend Laboratories, LLC: Amlodipine and Olmesartan Medoxomil Tablets
Hazard (FDA): Failed Dissolution Specifications: Olmesartan Medoxomil content below specifications
FDAMedicines
Dissolution
Ascend Laboratories, LLC: Ascend Laboratories
Hazard (FDA): Failed Dissolution Specifications
FDAMedicines
Dissolution
Ascend Laboratories, LLC: Atorvastatin Calcium Tablets USP and 3 more
Hazard (FDA): Failed Dissolution Specifications
FDAMedicines
Dissolution
Ascend Laboratories, LLC: Amlodipine and Olmesartan Medoxomil Tablets
Hazard (FDA): Failed Dissolution Specifications: low dissolution results
FDAMedicines
Ascend Laboratories, LLC: Rizatriptan Benzoate Tablets and 1 more
Hazard (FDA): CGMP Deviations: detection of N-nitroso-dimethyl-rizatriptan impurity, above the FDA recommended acceptable intake limit.
FDAMedicines
Ascend Laboratories, LLC: Cephalexin for Oral Suspension and 1 more
Hazard (FDA): Failed Impurities/Degradation Specifications An out-of-specification result was observed in the related substance test at the sixth month of stability analysis. The individual impurity was identified to be Cephalexin…
FDAMedicines
Ascend Laboratories, LLC: Dabigatran Etexilate and 1 more
Hazard (FDA): CGMP Deviations: Presence of N-nitroso-Dabigatran impurity above recommended interim limit
FDAMedicines